Table 1.
Baseline demographic characteristics
| Variable | n = 83 | |
|---|---|---|
| Age (years) | 74.0 | (65.5–78.5) |
| Sex (male) (%) | 51.0 | (61.4) |
| Cancer (%) | 40.0 | (48.2) |
| Coronary artery disease (%) | 4.0 | (4.8) |
| Diabetes mellitus (%) | 10.0 | (12.0) |
| Hypertension (%) | 21.0 | (25.3) |
| Albumin (g/dL) | 2.3 | (1.8–3.0) |
| CRP (mg/dL) | 10.4 | (3.7–17.5) |
| WBC (× 109 l−1) | 10.9 | (5.4–15.4) |
| Neutrophil count (× 109 l−1) | 8.7 | (3.56–13.29) |
| Lymphocyte count (× 109 l−1) | 0.5 | (0.299–0.927) |
| Plt count (× 104 mm−3) | 17.8 | (11.5–26.5) |
| Fibrinogen (mg/dL) | 609.0 | (378–711) |
| Survival (dead) (%) | 26.0 | (31.3) |
| AKI (%) | 38.0 | (45.8) |
| ARDS (%) | 13.0 | (15.7) |
| Shock (%) | 48.0 | (57.8) |
| DIC (%) | 30.0 | (36.1) |
| Presepsin on Day 1 (pg/mL) | 1051.5 | (569–1819.3) |
| Presepsin on Day 2 (ng/mL) | 1016.5 | (538–2156) |
| Presepsin on Day 3 (ng/mL) | 802.0 | (480.5–1825) |
| Presepsin on Day 5 (ng/mL) | 1043.0 | (480–1616) |
| ΔPresepsin Day 2 - Day 1 (pg/mL) | −21.50 | (− 246.5–274.75) |
| ΔPresepsin Day 3 - Day 1 (pg/mL) | −38.50 | (− 748.5–304) |
| ΔPresepsin Day 5 - Day 1 (pg/mL) | −59.50 | (− 745.75–635.5) |
| GPS | 1.0 | (1–2) |
| NLR | 12.6 | (4.53–26.35) |
| PLR | 321.9 | (195.63–543.69) |
| PI | 1.0 | (1–2) |
| PNI | 26.6 | (21.26–33.72) |
| SOFA | 8.0 | (5–11) |
| qSOFA | 2.0 | (1–3) |
CRP C-reactive protein, WBC white blood cell, AKI acute kidney injury, ARDS acute respiratory distress syndrome, DIC disseminated intravascular coagulation, GPS Glasgow Prognostic Score, NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, PI Prognostic Index, PNI Prognostic Nutritional Index, SOFA Sequential Organ Failure Assessment, qSOFA quick Sequential Organ Failure Assessment